{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:23:37Z","timestamp":1771464217307,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd013254","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T00:00:00Z","timestamp":1641340800000}}],"reference-count":99,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013254.pub2","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T15:25:41Z","timestamp":1641396341000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Intermittent prophylactic antibiotics for bronchiectasis"],"prefix":"10.1002","volume":"2022","author":[{"given":"Sally","family":"Spencer","sequence":"additional","affiliation":[{"name":"Health Research Institute, Faculty of Health, Social Care & Medicine; Edge Hill University; Ormskirk UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Donovan","sequence":"additional","affiliation":[{"name":"Medical Sciences, Institute of Health; University of Cumbria; Lancaster UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D","family":"Chalmers","sequence":"additional","affiliation":[{"name":"University of Dundee, Ninewells Hospital and Medical School; Dundee UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander G","family":"Mathioudakis","sequence":"additional","affiliation":[{"name":"Division of Infection, Immunity and Respiratory Medicine; The University of Manchester, Manchester Academic Health Science Centre; Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa J","family":"McDonnell","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine; Galway University Hospital; Galway Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Tsang","sequence":"additional","affiliation":[{"name":"Edge Hill University; Ormskirk UK"},{"name":"Department of Nursing, Faculty of Health, Social and Psychology; Manchester Metropolitan University; Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Leadbetter","sequence":"additional","affiliation":[{"name":"Medical School, Faculty of Health, Social Care and Medicine; Edge Hill University; Ormskirk UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"10.1002\/14651858.CD013254.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): Two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"issue":"Suppl 64","key":"10.1002\/14651858.CD013254.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1183\/13993003.congress-2020.2365","article-title":"Inhaled antibiotics improve symptoms of cough and sputum in patients with bronchiectasis: a post-hoc analysis of the AIR-BX studies","volume":"56","author":"Crichton","year":"2020","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD013254.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"2000608","DOI":"10.1183\/13993003.00608-2020","article-title":"Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies","volume":"56","author":"Crichton","year":"2020","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0004|cit4","unstructured":"Safety and effectiveness of AZLI (an inhaled antibiotic) in adults with non-cystic fibrosis bronchiectasis (AIR-BX1) clinicaltrials.gov\/ct2\/show\/NCT01313624"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"A5714","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A5714","article-title":"Airway bacterial load and response to inhaled aztreonam in bronchiectasis","volume":"199","author":"Vidal","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0007|cit7","unstructured":"Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis (AIR-BX2) clinicaltrials.gov\/ct2\/show\/NCT01314716"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0008|cit8","first-page":"A6201","article-title":"Efficacy and safety of different doses of tobramycin inhalation powder in patients with bronchiectasis and pulmonary pseudomonas aeruginosa infection: results from the ibest-1 study","volume":"201","author":"Loebinger","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 64","key":"10.1002\/14651858.CD013254.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1183\/13993003.congress-2020.4105","article-title":"Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study","volume":"56","author":"Loebinger","journal-title":"European Respiratory Journal"},{"issue":"suppl 62","key":"10.1002\/14651858.CD013254.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"PA2669","DOI":"10.1183\/13993003.congress-2018.PA2669","article-title":"A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1)","volume":"52","author":"Loebinger","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Loebinger MR Polverino E Blasi F Elborn SJ Chalmers JD Tiddens HAWM Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1) Pulmonary Pharmacology and Therapeutics 2019 58 101834 10.1016\/j.pupt.2019.101834","DOI":"10.1016\/j.pupt.2019.101834"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2001451","DOI":"10.1183\/13993003.01451-2020","article-title":"Efficacy and safety of TOBI Podhaler\u00ae in pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study","volume":"57","author":"Loebinger","year":"2021","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0013|cit13","unstructured":"Dose-finding study to assess the efficacy, safety and tolerability of tobramycin inhalation powder in patients with non-cystic fibrosis bronchiectasis and pulmonary p. aeruginosa infection (iBEST-1) clinicaltrials.gov\/ct2\/show\/NCT02712983"},{"issue":"3","key":"10.1002\/14651858.CD013254.pub2-BIB0014|cit14","first-page":"A27","article-title":"Dual release ciprofloxacin for inhalation (DRCFI) improves time to first exacerbation in bronchiectasis","volume":"24","author":"Cipolla","year":"2011","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0015|cit15","first-page":"A4866","article-title":"Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa density and increases time to first exacerbation in a 168 day placebo controlled study in non-cystic fibrosis bronchiectasis","volume":"183","author":"Serisier","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013254.pub2-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"issue":"8","key":"10.1002\/14651858.CD013254.pub2-BIB0017|cit17","first-page":"1928","article-title":"Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum p seudomonas aeruginosa (PA) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) bronchiectasis (BE)","volume":"38","author":"Serisier","year":"2011","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD013254.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"2000110","DOI":"10.1183\/13993003.00110-2020","article-title":"Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies","volume":"56","author":"Chalmers","year":"2020","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"A5713","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A5713","article-title":"Inhaled ciprofloxacin (ARD-3150) in patients with non-cystic fibrosis bronchiectasis and frequent pulmonary exacerbations: a pooled analysis from ORBIT-3 and ORBIT-4","volume":"201","author":"Chalmers","year":"2020","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"OA466","DOI":"10.1183\/1393003.congress-2017.OA466","article-title":"Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of pseudomonas aeruginosa (PA) susceptibility at baseline","volume":"50","author":"Froehlich","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD013254.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): Two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"A11","DOI":"10.1055\/s-0036-1592235","article-title":"A phase 3 study design of Pulmaquin in non-cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with pseudomonas aeruginosa (PA)","volume":"70","author":"O'Donnell","year":"2016","journal-title":"Pneumologie"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"PA2682","DOI":"10.1183\/13993003.congress-2018.PA2682","article-title":"Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections","volume":"52","author":"O'Donnell","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"PA357","DOI":"10.1183\/13993003.congress-2018.PA357","article-title":"Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB)","volume":"52","author":"O'Donnell","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0025|cit25","first-page":"A1775","article-title":"ORBIT-3 and ORBIT-4: Design of a phase 3 program to investigate safety and efficacy of pulmaquin\u00ae in non-cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with pseudomonas aeruginosa (PA)","volume":"193","author":"O'Donnell","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0026|cit26","unstructured":"Phase 3 study with ciprofloxacin dispersion for inhalation in non-CF bronchiectasis (ORBIT-3) clinicaltrials.gov\/ct2\/show\/NCT01515007"},{"issue":"12","key":"10.1002\/14651858.CD013254.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.cmi.2019.04.017","article-title":"Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection","volume":"25","author":"VanDevanter","year":"2019","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"OA466","DOI":"10.1183\/1393003.congress-2017.OA466","article-title":"Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of pseudomonas aeruginosa (PA) susceptibility at baseline","volume":"50","author":"Froehlich","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD013254.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): Two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respiratory Medicine"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0030|cit30","unstructured":"Phase 3 study with ciprofloxacin dispersion for inhalation in non-CF bronchiectasis (ORBIT-4) clinicaltrials.gov\/ct2\/show\/NCT02104245"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"A11","DOI":"10.1055\/s-0036-1592235","article-title":"A phase 3 study design of Pulmaquin in non-cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with pseudomonas aeruginosa (PA)","volume":"70","author":"O'Donnell","year":"2016","journal-title":"Pneumologie"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"PA2682","DOI":"10.1183\/13993003.congress-2018.PA2682","article-title":"Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections","volume":"52","author":"O'Donnell","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"PA357","DOI":"10.1183\/13993003.congress-2018.PA357","article-title":"Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB)","volume":"52","author":"O'Donnell","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0034|cit34","first-page":"A1775","article-title":"ORBIT-3 and ORBIT-4: design of a phase 3 program to investigate safety and efficacy of Pulmaquin\u00ae in non-cystic fibrosis bronchiectasis (NCFBE) patients chronically colonized with pseudomonas aeruginosa (PA)","volume":"193","author":"O'Donnell","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"12","key":"10.1002\/14651858.CD013254.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.cmi.2019.04.017","article-title":"Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection","volume":"25","author":"VanDevanter","year":"2019","journal-title":"Clinical Microbiology and Infection"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cct.2017.05.007","article-title":"The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of ciprofloxacin dry powder for inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis","volume":"58","author":"Akasamit","year":"2017","journal-title":"Contemporary Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD013254.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1702052","DOI":"10.1183\/13993003.02052-201","article-title":"RESPIRE 1: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"OA272","DOI":"10.1183\/13993003.congress-2016.OA272","article-title":"RESPIRE 1: Ciprofloxacin DPI 32.5mg b.d. administered 14 day on\/off or 28 day on\/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB)","volume":"48","author":"De Soyza","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"A14","DOI":"10.1055\/s-0036-1592238","article-title":"Baseline therapies for bronchiectasis (non-CF etiology) vary by country-data from the RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI)","volume":"70","author":"De Soyza","year":"2016","journal-title":"Pneumologie"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"PA2617","DOI":"10.1183\/13993003.congress-2015.PA2617","article-title":"Baseline demographic profile of subjects of the phase 3 RESPIRE 1 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)","volume":"46","author":"De Soyza","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0041|cit41","unstructured":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis (Non-CF BE) (RESPIRE 1) clinicaltrials.gov\/ct2\/show\/results\/NCT01764841"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0042|cit42","first-page":"A7303","article-title":"Effects of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) on health-related quality of life in patients with non-cystic fibrosis bronchiectasis (NCFB): Results from the phase 3 respire 1 study","volume":"195","author":"Quittner","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cct.2017.05.007","article-title":"The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of ciprofloxacin dry powder for inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis","volume":"58","author":"Akasamit","year":"2017","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0044|cit44","first-page":"A7642","article-title":"RESPIRE 2: Ciprofloxacin DPI 32.5 Mg B.i.d. administered 14 days on\/off Or 28 days on\/off vs. placebo for 48 weeks in patients with non-cystic fibrosis bronchiectasis (NCFB)","volume":"195","author":"Aksamit","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013254.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0046|cit46","first-page":"A1768","article-title":"Baseline demographic profile of subjects of the phase 3 RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (NCFB)","volume":"193","author":"Aksamit","year":"2016","journal-title":"ATS Journals"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0047|cit47","unstructured":"Ciprofloxacin dry powder for inhalation (DPI) in non-cystic fibrosis bronchiectasis (Non-CF BE) (RESPIRE 2) clinicaltrials.gov\/ct2\/show\/NCT02106832"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0048|cit48","unstructured":"Intermittent versus daily therapy for nodular bronchiectatic Mycobacterium avium complex lung disease (iREC) rctportal.niph.go.jp\/en\/detail?trial_id=jRCTs031190008"},{"issue":"1","key":"10.1002\/14651858.CD013254.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"e000434","DOI":"10.1136\/bmjresp-2019-000434","article-title":"Multicentre, open label, randomised controlled trial comparing intermittent versus daily treatment for non-cavitary nodular\/bronchiectatic Mycobacterium avium complex lung disease with rifampicin, ethambutol and clarithromycin (iREC): study protocol","volume":"6","author":"Nakagawa","year":"2019","journal-title":"BMJ Open Respiratory Research"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013254.pub2-BIB0050|cit50","first-page":"88S","article-title":"Intermittent antibiotic treatment in patients with stable bronchiectasis: A comparative study between amoxycillin and cefonicid","volume":"3","author":"Lloberes","year":"1990","journal-title":"European Respiratory Journal"},{"issue":"154","key":"10.1002\/14651858.CD013254.pub2-BIB0051|cit51","doi-asserted-by":"publisher","first-page":"e190055","DOI":"10.1183\/16000617.0055-2019","article-title":"The biology of pulmonary exacerbations in bronchiectasis","volume":"28","author":"Amati","year":"2019","journal-title":"European Respiratory Review"},{"issue":"2","key":"10.1002\/14651858.CD013254.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"e1701953","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"Ara\u00fajo","year":"2018","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD013254.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013254.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molimm.2012.09.011","article-title":"Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis","volume":"55","author":"Chalmers","year":"2013","journal-title":"Molecular Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013254.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013254.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.00119114","article-title":"Management of bronchiectasis in adults","volume":"45","author":"Chalmers","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD013254.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"Chalmers","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013254.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5694\/j.1326-5377.2002.tb04733.x","article-title":"Bronchiectasis in indigenous children in remote Australian communities","volume":"177","author":"Chang","year":"2002","journal-title":"Medical Journal of Australia"},{"issue":"6","key":"10.1002\/14651858.CD013254.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.5694\/j.1326-5377.2010.tb03949.x","article-title":"Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand","volume":"193","author":"Chang","year":"2010","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0060|cit60","first-page":"6","article-title":"Inflammation: a two-edged sword - the model of bronchiectasis","volume":"147 Suppl","author":"Cole","year":"1986","journal-title":"European Journal of Respiratory Diseases"},{"issue":"Suppl A","key":"10.1002\/14651858.CD013254.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/40.suppl_1.5","article-title":"The damaging role of bacteria in chronic lung infection","volume":"40","author":"Cole","year":"1997","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD013254.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1479972316643698","article-title":"Annual direct medical costs of bronchiectasis treatment: impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence","volume":"13","author":"De la Rosa","year":"2016","journal-title":"Chronic Respiratory Disease"},{"issue":"6","key":"10.1002\/14651858.CD013254.pub2-BIB0063|cit63","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012733.pub2","article-title":"Continuous versus intermittent antibiotics for bronchiectasis","author":"Donovan","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD013254.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1183\/09031936.96.09081601","article-title":"Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa","volume":"9","author":"Evans","year":"1996","journal-title":"European Respiratory Journal"},{"issue":"11","key":"10.1002\/14651858.CD013254.pub2-BIB0065|cit65","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0066|cit66","first-page":"68","volume-title":"Bronchiectasis. European Respiratory Society Monographs","volume":"52","author":"Foweraker","year":"2011"},{"issue":"5","key":"10.1002\/14651858.CD013254.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"658-70","DOI":"10.4187\/aarc0537","article-title":"Aerosol antibiotics in cystic fibrosis","volume":"54","author":"Geller","year":"2009","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0068|cit68","volume-title":"European Lung White Book: Respiratory Health and Disease in Europe","author":"Gibson","year":"2013"},{"issue":"1","key":"10.1002\/14651858.CD013254.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1183\/13993003.01567-2015","article-title":"Bronchiectasis: how to be an orphan with many parents?","volume":"47","author":"Goeminne","year":"2016","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0070|cit70","unstructured":"GRADEpro GDT Grade Working Group, McMaster University (developed by Evidence Prime) 2015"},{"issue":"3","key":"10.1002\/14651858.CD013254.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4103\/1817-1737.82443","article-title":"Clinical, radiologic, and functional evaluation of 304 patients with bronchiectasis","volume":"6","author":"Habesoglu","year":"2011","journal-title":"Annals of Thoracic Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013254.pub2-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011825","article-title":"Adverse events in patients taking macrolide antibiotics versus placebo for any indication","author":"Hansen","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0073|cit73","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"8","key":"10.1002\/14651858.CD013254.pub2-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001392.pub3","article-title":"Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults","author":"Hnin","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD013254.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jcrc.2013.04.008","article-title":"Previous antibiotic exposure and evolution of antibiotic resistance in mechanically ventilated patients with nosocomial infections","volume":"28","author":"Hui","year":"2013","journal-title":"Journal of Critical Care"},{"issue":"3","key":"10.1002\/14651858.CD013254.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40258-013-0027-z","article-title":"Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective","volume":"11","author":"Joish","year":"2013","journal-title":"Applied Health Economics and Health Policy"},{"issue":"4","key":"10.1002\/14651858.CD013254.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1378\/chest.11-0679","article-title":"The burden of disease in pediatric non-cystic fibrosis bronchiectasis","volume":"141","author":"Kapur","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD013254.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/15412555.2018.1540034","article-title":"COPD Assessment Test (CAT) is a valid and simple tool to measure the impact of bronchiectasis on affected patients","volume":"15","author":"Lanza","year":"2018","journal-title":"COPD"},{"issue":"5","key":"10.1002\/14651858.CD013254.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1378\/chest.07-0490","article-title":"Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis","volume":"132","author":"Mart\u00ednez-Garc\u00eda","year":"2007","journal-title":"Chest"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2466-14-107","article-title":"Treatment adherence and health outcomes in patients with bronchiectasis","volume":"14","author":"McCullough","year":"2014","journal-title":"BMC Pulmonary Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013254.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"273-83","DOI":"10.1111\/eva.12196","article-title":"The fitness costs of antibiotic resistance mutations","volume":"8","author":"Melnyk","year":"2015","journal-title":"Evolutionary Applications"},{"issue":"1","key":"10.1002\/14651858.CD013254.pub2-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1186\/s12879-017-2754-5","article-title":"Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations","volume":"17","author":"Men\u00e9ndez","year":"2017","journal-title":"BMC Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD013254.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2147\/COPD.S83910","article-title":"Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis: a systemic review and meta-analysis","volume":"10","author":"Ni","year":"2015","journal-title":"International Journal of Chronic Obstructive Pulmonary Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013254.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"i1-58","DOI":"10.1136\/thx.2010.136119","article-title":"British Thoracic Society guidelines for non-CF bronchiectasis","volume":"65","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD013254.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"pii: 1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD013254.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD013254.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1183\/20734735.007516","article-title":"Global impact of bronchiectasis and cystic fibrosis","volume":"12","author":"Redondo","year":"2016","journal-title":"Breathe"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0089|cit89","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, the Cochrane Collaboration 2020"},{"issue":"6","key":"10.1002\/14651858.CD013254.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1183\/13993003.00954-2015","article-title":"Bronchiectasis in Germany: a population-based estimation of disease prevalence","volume":"46","author":"Ringshausen","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD013254.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.rmed.2010.02.022","article-title":"Trends in bronchiectasis mortality in England and Wales","volume":"104","author":"Roberts","year":"2010","journal-title":"Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013254.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1513\/AnnalsATS.201310-335OC","article-title":"A novel microbiota stratification system predicts future exacerbations in bronchiectasis","volume":"11","author":"Rogers","year":"2014","journal-title":"Annals of the American Thoracic Society"},{"issue":"4","key":"10.1002\/14651858.CD013254.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1378\/chest.10-0099","article-title":"Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006","volume":"138","author":"Seitz","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD013254.pub2-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008481.pub2","article-title":"Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections","author":"Shiu","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD013254.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/adc.2004.066472","article-title":"New Zealand national incidence of bronchiectasis \"too high\" for a developed country","volume":"90","author":"Twiss","year":"2005","journal-title":"Archives of Disease in Childhood"},{"issue":"4","key":"10.1002\/14651858.CD013254.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.cpm.0000171422.98696.ed","article-title":"Prevalence and economic burden of bronchiectasis","volume":"12","author":"Weycker","year":"2005","journal-title":"Clinical Pulmonary Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013254.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1183\/09031936.97.10081754","article-title":"Effect of sputum bacteriology on the quality of life of patients with bronchiectasis","volume":"10","author":"Wilson","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD013254.pub2-BIB0098|cit98","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008695.pub2","article-title":"Short courses of antibiotics for children and adults with bronchiectasis","author":"Wurzel","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013254.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013254","article-title":"Intermittent prophylactic antibiotics for bronchiectasis","author":"Spencer","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T10:25:46Z","timestamp":1686738346000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013254.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,5]]},"references-count":99,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013254.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,5]]}}}